Buradasınız

Anasayfa » Content

Primer Santral Sinir Sistemi Lenfoması: Üç Olgu Sunumu

Primary Central Nervous System Lymphoma: Report Of Three Cases

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Primary central nervous system non-Hodgkin’s lymphoma (PCNSL) is an uncommon tumor, representing 0.85-2.0 % of all primary brain tumors. PCNSL occurs more frequently in congenital and acquired im-munodeficiency states, especially in acquired immunodeficiency syndrome (AIDS). Patients with sporadic PCNLS without HIV infection and immunosupression have traditionally been treated with radiotherapy (RT). For nonimmunosuppression patients, whole brain irradiation (40 to 50 Gy) with or without a local boost to the primary tumor (60 to 65 Gy) is suggested. Despite high clinical and radiological response rate and effective palliation, the disease mostly recurs with a median survival fallowing RT alone only 10-18 months and few long-term survivors. Improved survival with the addition of chemotherapy (CT) to RT has been suggested; but combined modality therapy did not produce an overall survival advantage in multiple trials.
Bookmark/Search this post with
Abstract (Original Language): 
Primer santral sinir sistemi (SSS) lenfomalarının görülme sıklığında son yıllarda artış olmakla birlikte tüm beyin tümörlerinin yaklaşık %0.85-2’sini oluştururlar. Konjenital ve kazanılmış immün yetmezlikli hastalarda (AIDS), özellikle AIDS ile birlikte primer SSS lenfomalarının görülme sıklığı artmıştır. Sporodik veya immünsüpresif primer SSS lenfomalarında tedavi yöntemi olarak radyoterapi (RT) daha sık kullanılmaktadır. İmmünsüpresif olmayan hastalarda, tüm beyin ışınlaması (40-50 Gy) ve primer tümöre yönelik lokal boost uygulaması başarılı sonuçlar vermiştir. Klinik ve radyolojik cevap oranlarının yüksek olmasına ve etkili palyasyon sağlanmasına rağmen tek başına radyoterapi ile rekürrens sık ve ortanca sağkalım 10-18 ay gibi kısa sürelidir. Radyoterapiye kemoterapinin (KT) eklenmesi ile sağkalımda gelişme sağlanabileceği düşünülmüştür, fakat kombine tedavi modellerinin kullanılmasıyla da sağkalımda gelişme elde edilememiştir
FULL TEXT (PDF): 
PDF icon arastirmax-primer-santral-sinir-sistemi-lenfomasi-uc-olgu-sunumu.pdf
  • 3
227-231
  • Turkish

REFERENCES

References: 

1. Fine HA, Mayer RJ. Primary central nervous system
lymphoma, Ann Int Med 1993;119:1093-104.
2. Hochberg FH, Miller DC. Primary central nervous system
lympoma. J Neurosurg 1998;68:835-53.
3. O’Neill BP, Illing JJ. Primary central nervous system
lympoma. Mayo Clin Proc 1989;64:1005-20.
4. Eby NL, Grufferman S, Flannelly CM, Schold SC, Vogel FS,
Burger PC. Increasing incidence of primary brain lymphoma
in the US. Cancer 1998;62:2461-5.
5. Wara WM, Bauman GS, Sneed PK, Larson DA, Karlsson
UL. Brain, brainstem, and cerebellum. In: Perez CA, Brady
LW (eds). Principles and Practise of Radiation Oncology.
Philadelphia: Lippincott-Raven; 1997. 777-828.
6. Ferreri AJM, Reni M, Villa E, et al. Primary central nervous
system lymphoma in immunocompetent patients. Cancer
Treat Rev 1995;21:415-46.
7. Hayabuchi N, Shibamoto Y, Onizuka Y. Primary Central
nervous system lympoma in Japan: A Nationwide survey. Int
J Radiation Oncology Biol Phys 1999;44(2):265-72.
8. Murray K, Kun L, Cox J. Primary malignant lymphoma of
the central nervous system. J Neurosurg 1986;65:600-7.
9. Socie G, Piprot-Chauffat C, Schlienger M, et al. Primary
lympoma of the central nervous system, an unresolved
therapeutic problem. Cancer 1990;65:322-6.
10. O’Neill BP, Dinapoli RP, Kurtin PJ, Habermann TB. Occult
systemic non-Hodgkin's lymphoma (NHL) in patients
initially diagnosed as primary central nervous system
lymphoma (PCNSL): how much staging is enough? J
Neurooncol 1995;25(1):67-71. Primer Santral Sinir Sistemi Lenfoması
231
11. Lachance DH, O’Neill BP, Macdonald DR, et al. Primary
leptomeningeal lymphoma: report for 9 cases, diagnosis with
immunocytochemieal analysis, and rewiew of the literature.
Neurology 1991;95:41.
12. Scott TF, Hogan EL, Carter TD, Garen PD, Brillman J,
Kurent JE. Primary intracranial meningeal lymphoma. Am J
Med 1990;89:536-8.
13. Deangelis LM, Yahalom J, Rosenblum M, Posner JB.
Primary CNS lymphoma: managing patients with
spontaneous and AIDS-related disease. Oncology 1987;
1:52-62.
14. Deangelis LM, Yahalom J. Primary central nervous system
lymphoma. In: DeVita VT, Hellman S, Rosenberg SA (eds).
Cancer-Principles&Practice of Oncology. Philadelphia:
Lippincott Williams&Wilkins; 2001. 2330-9.
15. Balmaceda C, Gaynor JJ, Sun M, Gluck JT, De Angelis LM.
Leptomeningeal tumor in primary central nervous system
lympoma: recognition, significance, and implications. Ann
Neurol 1995; 38:202-9.
16. Deangelis LM, Yahalom J, Heinemann MH, Cirrincione C,
Thaler HT, Krol G. Primary CNS lymphoma: combined
treatment with chemotherapy and radiotherapy. Neurology
1990; 40:80-6.
17. Schwaighofer BW, Hesselink JR, Press GA, Wolf RL, Healy
ME, Berthoty DP. Primary intracranial CNS lymphoma. MR
manifestations. AJNR Am J Neuroradiol 1989;10:725-9.
18. Rubin M, Libman I, Brisson M, L. Spontaneous temporary
remission in primary CNS lymphoma. Can J Neurol Sci
1987;14:175-7.
19. Vaguero J, Martinez R, Rossi E, Lopez R. Primary cerebral
lymphoma: The “Ghost tumor”. J Neuro Surg 1984;60: 174-
6.
20. Burstein SD, Kernohan JW, Vihlein A. Neoplasms of
reticulo-endothelial system of the brain cancer 1963;16:289.
21. Henry JM, Heffner RR Jr, Dillard SH, Earle KM, Davis RL.
Primary malignant lymphomas of the central nervous system.
Cancer 1974;34:1293:302.
22. Woodman R, Shin K, Pineo G. Primary non-Hodgkin’s
lymphoma of the brain. A review. Medicine (Baltimore)
1985;64:425-30.
23. Deangelis LM. Current management of primary central
nervous system lymphoma. Oncology 1995;9:63-71.
24. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's
lymphoma of the brain: can high dose, large volume
radiation therapy improve survival? Report on a prospective
trial by the Radiation Therapy Oncology Group (RTOG):
RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23(1):247-
8.
25. Deangelis LM, Yahalom J, Thaler HT, Kher U. Combined
modality treatment for primary CNS lymphoma. J Clin
Oncol 1992; 10:635-43.
26. Lachance DH, Brizel DM, Gockerman JP, et al.
Cyclophosphamide, doxorubicin, vincristine, and prednisone
for primary central nervous system lymphoma: shortduration response and multifocal intracerebral recurrence
preceding radiotherapy. Neurology 1994;44:1721-7.
27. Brada M, Hjiyiannalus D, Hines F, Traish D, Ashley S. Short
intensive Primary CT and RT in sporadic PCNSL. Int J
Radiat Oncol Biol Phys 1998;40:1157-62.
28. O’Neill B, Hva wang C, O’Fallon J. PCNSL survival
advantages with combined initial therapy? A final report of
the NCCTG study 86-72-52. Int J Radiat Oncol Biol Phys
1999;43:559-63.
29. Schultz C, Scott C, Sherman W, et al. Preirradiation
chemotherapy with CHOP for primary CNS lymphomas.
Initial report of RTOG protocol 88-06. J Clin Oncol
1996;14:556.
30. O’Neill BP, O’Falton JR, Earle JD, et al. PCNS non-
Hodgkin’s lymphoma: survival advantage with combined
initial therapy? Int J Radiat Oncol Biol Phys 1995;33:663.
31. Liang BC, Grant R, Junck L, et al. Primary central nervous
system lymphoma treatment with multiagent systemic and
intrathecal chemotherapy with radiotherapy. Int J Oncol
1993;3:1001.
32. Dubuisson A, Kaschten B, Lénelle J, et al. PCNSL report of
32 cases and review of the literature. Clinical Neurology
(2004) (Article in press).
33. Rampen RHJ, van Andel JG, Sizoo W, Van Unnik JAM.
Radiationtherapy in primary NHL of the CNS. Eur J Cancer.
1980;16:177.
34. Reni M, Ferrer; AJM, Garancini MP, Villa E. Therapeutic
management of primary central nervous system lymphoma in
immunocompotent patients: results of a critical review of the
literature. Ann Oncol 1997;8:227.
35. Blay JY, Conray T, Chevreau C, et al. High-dose
methotrexate for the treatment of primary cerebreal
lymphomas: analysis of survival and late neurologic toxicity
in a retrospective series. J Clin Oncol 1998;16:864.
36. De Angelis LM. Primary CNS lymphoma: treatment with
combined chemotherapy and radiotherapy. J Neurooncol
1999;43:249.
37. Littley MD, Shalet SM, Beardwell CG, et al.
Hypopituitarism following extrenal radiotherapy for pituitary
tumours in adults. Q J Med 1989;70:145-60.
38. Lam KSL, Tse UKC, Wang C, et al. Effects of cranial
irradiation on hypothalamic pituitary function a 5 year
longitudinal study in patients with nasopharyngeal
carcinoma. Q. J. Med. 1991;78:165-76.
39. Shalet SM, Beardwell CG, Morris Joner PH, Pearson D.
Pituitary function after treatment of intracranial tumours in
children. Lancet 1975; (ii):104-7.
40. Samaran NA, Vieto R, Schultz PN, et al. Hypothalamic
pituitary disfunction after radiotherapy to the head and neck.
Int J Radiat Oncol Biol Phys 1982;8:1857-67.
41. Shalet SM, Beardwell CG, Pearson D, et al. The effect of
varying doses of cerebral irradiation on growth hormone
production in childhood. Clin Endocrinol 1976;5:287-90.
42. Littley MD, Shalet SM, Beardwell CG, et al. radiation
induced hypopituitarism is dose dependent. Clin Endocrinol
1989;31:363-73.
43. Toogood AA. Endocrine consequences of brain irradiation.
Growth Hormone and IGF Research 2004;14:118-24.
44. Merchut MP, Haberland C, Naheedy MH, Rubino FA. Long
survival of primary cerebral lymphoma with progressive
radiation necrosis. Neurology 1985;35:552.

Thank you for copying data from http://www.arastirmax.com